Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The CheckMate 649 trial eligibility criteria identified patients with better prognoses in advanced gastric cancer. Patients not meeting these criteria had poorer outcomes and less access to further chemotherapy.
Area Of Science
- Oncology
- Clinical Trials
- Gastrointestinal Cancers
Background
- The CheckMate 649 trial established clinical benefits of nivolumab plus chemotherapy for HER2-negative advanced gastric cancer.
- Discrepancies exist between randomized controlled trial eligibility and clinical practice, potentially affecting patient outcomes.
- The clinical significance of CheckMate 649 eligibility criteria in real-world settings requires evaluation.
Purpose Of The Study
- To assess the clinical significance of CheckMate 649 eligibility criteria in patients with HER2-negative metastatic gastric cancer.
- To identify prognostic factors influencing treatment outcomes in clinical practice.
- To understand the impact of trial eligibility on subsequent chemotherapy and overall survival.
Main Methods
- Retrospective analysis of 160 patients with HER2-negative metastatic gastric cancer receiving chemotherapy.
- Classification of patients into eligible and ineligible groups based on CheckMate 649 criteria.
- Comparison of second- and third-line chemotherapy rates, overall survival, and prognostic factors between groups.
Main Results
- 47.5% of patients were eligible, and 52.5% were ineligible for CheckMate 649 criteria.
- The ineligible group showed significantly lower rates of second- and third-line chemotherapy (P=0.02).
- Median overall survival was 22.9 months for eligible vs. 10.5 months for ineligible patients (P<0.01), indicating a poorer prognosis for the ineligible group. Disease control was an independent prognostic factor in both groups.
Conclusions
- CheckMate 649 eligibility criteria are associated with significant differences in chemotherapy access and prognosis for advanced gastric cancer patients in clinical practice.
- Patients with poor general condition, often meeting ineligibility criteria, face worse outcomes.
- These findings highlight the importance of considering real-world patient characteristics beyond trial eligibility for optimizing treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...